5e70ba2109b32d0004a916bd_1.jpg
Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel
March 17, 2020 13:06 ET | Todos Medical Ltd.
 3DMed test demonstrated 99.3% sensitivity and 100% specificity in Chinese clinical trial Nucleic Acid test performed on proprietary automated platform to increase throughput CE Mark and China FDA...
5e70ba2109b32d0004a916bd_1.jpg
UPDATE: Todos Medical Enters Into Coronavirus Nucleic Acid Buccal Testing Kit Distribution Agreement With 3D BioMed
March 17, 2020 11:30 ET | Todos Medical Ltd.
3D BioMed test demonstrated 99.3% sensitivity and 100% specificity in Chinese clinical trial Nucleic Acid test performed on proprietary automated platform to increase throughput CE Mark and Chinese...
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International
February 06, 2020 08:11 ET | Amarantus Bioscience Holdings, Inc.
New York, NY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary...
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Amarantus Releases Letter to Shareholders
February 04, 2020 09:54 ET | Amarantus Bioscience Holdings, Inc.
New York, NY, Feb. 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary...
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori
January 30, 2020 09:05 ET | Amarantus Bioscience Holdings, Inc.
 Strong customer retention at both stores in Dallas, TX with growing online presence Focus  on delivering wellness solutions by engaging customers to participate in clinical studies and provide...
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products
January 02, 2020 08:14 ET | Amarantus Bioscience Holdings, Inc.
 Emerald gains exclusive worldwide development rights to ESS, MANF and PhenoGuard Amarantus receives Emerald preferred stock valued at a minimum of $66.6 million New York, NY, Jan. 02,...
TodosMedical.png
Todos To Present At Upcoming 12th Annual LD Micro Main Event
December 06, 2019 07:29 ET | Todos Medical Ltd.
REHOVOT, Israel, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection...
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease
December 04, 2019 07:36 ET | Amarantus Bioscience Holdings, Inc.
·        Patent extends patent coverage for eltoprazine to 2034 New York, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS)...
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics
November 21, 2019 08:00 ET | Amarantus Bioscience Holdings, Inc.
Patent covers use of MANF in Glaucoma, Wolfram Syndrome and Retinitis Pigmentosa New York, NY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC...
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Amarantus Provides Recapitalization Update to Shareholders
November 18, 2019 08:30 ET | Amarantus Bioscience Holdings, Inc.
Pending license with Emerald provides opportunity to realize therapeutic portfolio valueJV w/Todos announces full enrollment for LymPro Alzheimer’s blood test clinical trialAmarantus management...